Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20265607 | 0.76 | ASIC3 (0.51) | ASIC3TRPA1MAOA | |
| SCHEMBL7013099 | 0.72 | TRPA1 (0.54) | ASIC3TRPA1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8024180 | 0.69 | CYP2A6 (0.48) | ASIC3TRPA1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13178569 | 0.68 | ASIC3 (0.44) | ASIC3TRPA1CYP2A6 | |
| SCHEMBL658129 | 0.66 | ASIC3 (0.41) | ASIC3TRPA1CYP3A4CYP2A6MAOA | |
| SCHEMBL26928464 | 0.65 | ASIC3 (0.51) | ASIC3TRPA1TNF | |
| SCHEMBL30737893 | 0.65 | ASIC3 (0.51) | ASIC3TRPA1TNF | |
| SCHEMBL30812428 | 0.65 | TRPA1 (0.42) | ASIC3TRPA1CYP2A6MAOA | |
| SCHEMBL30491673 | 0.65 | NOS3 (0.43) | ASIC3TRPA1MAOA | |
| SCHEMBL658524 | 0.65 | NOS3 (0.43) | ASIC3TRPA1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | ASIC3 3137/4885TRPA1 1637/4885TNF 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.